January 8, 2015 /
By RTT News, January 08, 2015, 07:50:00 AM EDT
Drugmaker Biogen Idec ( BIIB ) Thursday announced top-line results from the Phase 2 acute optic neuritis or AON RENEW trial in which treatment with anti-LINGO-1 showed evidence of biological repair of the visual system.
Anti-LINGO-1 demonstrated an improvement in the study’s primary endpoint, recovery of optic nerve latency, relative to placebo. The study showed no effect on secondary endpoints, including change in thickness of the retinal layers and visual function.
AON damages the optic nerve, causing loss of the myelin sheath and axonal injury, and may result in loss of visual function. It is considered a good clinical model to measure the hypothesized mechanisms of action of anti-LINGO-1, remyelination and neuroprotection.
Read more
Or read another article here: Biogen Idec Reports Positive Top-Line Results from Phase 2 Anti-LINGO-1 Trial in People with Acute Optic Neuritis …
~~~~~~~~~~~~~~~~~~~~
.
.
.
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
Stay informed with MS news and information - Sign-up here
For MS patients, caregivers or clinicians, Care to chat about MS? Join Our online COMMUNITY CHAT
